JP2012105650A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012105650A5 JP2012105650A5 JP2011277848A JP2011277848A JP2012105650A5 JP 2012105650 A5 JP2012105650 A5 JP 2012105650A5 JP 2011277848 A JP2011277848 A JP 2011277848A JP 2011277848 A JP2011277848 A JP 2011277848A JP 2012105650 A5 JP2012105650 A5 JP 2012105650A5
- Authority
- JP
- Japan
- Prior art keywords
- complex
- substitution
- amino acid
- a3ay
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000006467 substitution reaction Methods 0.000 claims 29
- 102220494690 Small vasohibin-binding protein_K32E_mutation Human genes 0.000 claims 18
- 102220494687 Small vasohibin-binding protein_R36E_mutation Human genes 0.000 claims 17
- 230000037431 insertion Effects 0.000 claims 11
- 238000003780 insertion Methods 0.000 claims 11
- 102220595361 Anamorsin_A34E_mutation Human genes 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 125000000539 amino acid group Chemical group 0.000 claims 6
- 208000032843 Hemorrhage Diseases 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 208000034158 bleeding Diseases 0.000 claims 4
- 230000000740 bleeding effect Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 238000001727 in vivo Methods 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 230000004988 N-glycosylation Effects 0.000 claims 3
- 108010054265 Factor VIIa Proteins 0.000 claims 2
- 108010014173 Factor X Proteins 0.000 claims 2
- 208000031220 Hemophilia Diseases 0.000 claims 2
- 208000009292 Hemophilia A Diseases 0.000 claims 2
- 229940012414 factor viia Drugs 0.000 claims 2
- 230000013595 glycosylation Effects 0.000 claims 2
- 238000006206 glycosylation reaction Methods 0.000 claims 2
- 229940099816 human factor vii Drugs 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 206010046996 Varicose vein Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000035602 clotting Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47978003P | 2003-06-19 | 2003-06-19 | |
| US60/479,780 | 2003-06-19 | ||
| DKPA200400930 | 2004-06-15 | ||
| DKPA200400930 | 2004-06-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006515723A Division JP4915918B2 (ja) | 2003-06-19 | 2004-06-18 | 第ＶＩＩ因子または第ＶＩＩａ因子のＧｌａドメイン変種 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012105650A JP2012105650A (ja) | 2012-06-07 |
| JP2012105650A5 true JP2012105650A5 (enExample) | 2013-03-07 |
| JP5580283B2 JP5580283B2 (ja) | 2014-08-27 |
Family
ID=33553697
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006515723A Expired - Fee Related JP4915918B2 (ja) | 2003-06-19 | 2004-06-18 | 第ＶＩＩ因子または第ＶＩＩａ因子のＧｌａドメイン変種 |
| JP2011277848A Expired - Fee Related JP5580283B2 (ja) | 2003-06-19 | 2011-12-20 | 第ＶＩＩ因子または第ＶＩＩａ因子のＧｌａドメイン変種 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006515723A Expired - Fee Related JP4915918B2 (ja) | 2003-06-19 | 2004-06-18 | 第ＶＩＩ因子または第ＶＩＩａ因子のＧｌａドメイン変種 |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US20050164932A1 (enExample) |
| EP (1) | EP1644504B8 (enExample) |
| JP (2) | JP4915918B2 (enExample) |
| KR (1) | KR101191779B1 (enExample) |
| CN (1) | CN1839203B (enExample) |
| AT (1) | ATE458057T1 (enExample) |
| AU (2) | AU2004247799B2 (enExample) |
| BR (1) | BRPI0411650A (enExample) |
| CA (1) | CA2529828C (enExample) |
| CY (1) | CY1109984T1 (enExample) |
| DE (1) | DE602004025576D1 (enExample) |
| DK (1) | DK1644504T3 (enExample) |
| ES (1) | ES2338425T3 (enExample) |
| HR (1) | HRP20100264T1 (enExample) |
| IL (1) | IL172364A (enExample) |
| MX (1) | MXPA05013769A (enExample) |
| NZ (2) | NZ544728A (enExample) |
| PL (1) | PL1644504T3 (enExample) |
| PT (1) | PT1644504E (enExample) |
| RU (1) | RU2373282C2 (enExample) |
| SI (1) | SI1644504T1 (enExample) |
| WO (1) | WO2004111242A1 (enExample) |
| ZA (1) | ZA200600539B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL204285B1 (pl) | 2000-02-11 | 2009-12-31 | Bayer Healthcare Llc | Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego |
| BR0309576A (pt) * | 2002-04-30 | 2005-02-09 | Maxygen Holdings Ltd | Variante de polipeptìdeo do fator vii (fvii) ou fator viia (fviia), sequência de nucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, uso de uma variante, e, método para tratar um mamìfero que tenha uma doença ou um distúrbio em que a formação de coágulo é desejável |
| AU2004221761B2 (en) * | 2003-03-20 | 2010-01-07 | Bayer Healthcare Llc | FVII or FVIIa variants |
| DE602004025576D1 (de) | 2003-06-19 | 2010-04-01 | Bayer Healthcare Llc | Varianten der faktor-vii- oder -viia-gla-domäne |
| MX2007001294A (es) | 2004-08-17 | 2008-03-04 | Zlb Behring Gmbh | Polipeptidos modificados que dependen de vitamina k. |
| US20080188400A1 (en) * | 2005-04-26 | 2008-08-07 | Maxygen Holdings Ltd. | Methods For Treating Bleeding |
| JP5335422B2 (ja) | 2005-06-17 | 2013-11-06 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 少なくとも１つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化 |
| JP5147692B2 (ja) | 2005-07-13 | 2013-02-20 | ノボ ノルディスク ヘルス ケア アーゲー | 治療用タンパク質生成のための宿主細胞タンパク質ノックアウト細胞 |
| WO2007013993A1 (en) * | 2005-07-22 | 2007-02-01 | Maxygen Holdings, Ltd. | In-solution activation of factor vii |
| EP1924689B1 (en) | 2005-09-01 | 2014-08-13 | Novo Nordisk Health Care AG | Hydrophobic interaction chromatography purification of factor vii polypeptides |
| JP5690047B2 (ja) | 2005-09-14 | 2015-03-25 | ノボ ノルディスク ヘルス ケア アーゲー | ヒト凝固第ｖｉｉ因子ポリペプチド |
| US8383388B2 (en) * | 2006-06-19 | 2013-02-26 | Catalyst Biosciences, Inc. | Modified coagulation factor IX polypeptides and use thereof for treatment |
| EP2059527B1 (en) | 2006-09-01 | 2014-12-03 | Novo Nordisk Health Care AG | Modified glycoproteins |
| FR2910969B1 (fr) * | 2006-12-29 | 2009-02-27 | Lab Francais Du Fractionnement | Procede de mesure de la concentration de facteur viia (fviia) dans un echantillon |
| EP1952822A1 (en) * | 2007-01-26 | 2008-08-06 | Novo Nordisk A/S | Factor VII polypeptides with increased affinity to platelets |
| WO2008127702A2 (en) * | 2007-04-13 | 2008-10-23 | Catalyst Biosciences, Inc. | Modified factor vii polypetides and uses thereof |
| TWI465247B (zh) | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子ｖｉｉ多肽和其用途 |
| WO2010149172A2 (en) | 2009-06-24 | 2010-12-29 | Rigshospitalet | SYSTEMIC PRO-HEMOSTATIC EFFECT OF CLOTTING FACTORS IN COMBINATION WITH SYMPATHICOMIMETICS WITH AGONISTIC EFFECTS ON α-ADRENERGIC AND/OR β-ADRENERGIC RECEPTORS OF THE SYMPATHETIC NERVOUS SYSTEM, RELATED TO IMPROVED CLOT STRENGTH. |
| FR2947181B1 (fr) * | 2009-06-26 | 2012-05-04 | Lfb Biotechnologies | Composition de facteur vii |
| US12203113B2 (en) | 2009-07-09 | 2025-01-21 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| TWI595004B (zh) | 2010-11-03 | 2017-08-11 | 介控生化科技公司 | 經修飾之第九因子多胜肽及其用途 |
| MX380585B (es) * | 2012-12-24 | 2025-03-12 | Coagulant Therapeutics Corp | Polipeptidos del factor vii de acción corta. |
| PT3524617T (pt) | 2013-03-15 | 2023-07-12 | Gladiator Biosciences Inc | Domínios gla como agentes terapêuticos |
| CN104211802B (zh) * | 2013-05-29 | 2018-07-27 | 成都渊源生物科技有限公司 | 人凝血因子轻链蛋白及其应用 |
| WO2016092550A2 (en) | 2014-12-10 | 2016-06-16 | Opko Biologics Ltd. | Methods of producing long acting ctp-modified polypeptides |
| JP2019515904A (ja) * | 2016-04-14 | 2019-06-13 | アイコニック セラピューティクス，インコーポレイテッド | 新血管新生に関連する障害を治療するための組成物および方法 |
| BR112019000610A2 (pt) | 2016-07-11 | 2019-07-02 | Opko Biologics Ltd | fator vii de coagulação de longa ação e métodos de produção do mesmo |
| PE20201462A1 (es) | 2017-09-05 | 2020-12-17 | Gladiator Biosciences Inc | Metodo de direccionamiento de exosomas |
| US20210069306A1 (en) | 2019-08-15 | 2021-03-11 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides for subcutaneous administration and on-demand treatment |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA862768B (en) * | 1985-04-17 | 1986-12-30 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| GR860984B (en) * | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| US5180583A (en) * | 1985-11-26 | 1993-01-19 | Hedner Ulla K E | Method for the treatment of bleeding disorders |
| US5258288A (en) * | 1986-07-25 | 1993-11-02 | Genzyme Corporation | Vector containing DNA encoding mature human protein S |
| DK323587D0 (da) | 1987-06-25 | 1987-06-25 | Novo Industri As | Protein |
| PT87688B (pt) | 1987-06-12 | 1992-09-30 | Hoechst Japan | Processo para a preparacao de proteina hibrida c |
| US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| US5648254A (en) * | 1988-01-15 | 1997-07-15 | Zymogenetics, Inc. | Co-expression in eukaryotic cells |
| JPH0246296A (ja) | 1988-08-09 | 1990-02-15 | Hoechst Japan Ltd | 雑種プロテインｃ及びその製造方法 |
| US5218092A (en) | 1988-09-29 | 1993-06-08 | Kyowa Hakko Kogyo Co., Ltd. | Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains |
| US5041376A (en) * | 1988-12-09 | 1991-08-20 | The Board Of Regents Of The University Of Texas System | Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins |
| US5093317A (en) * | 1989-06-05 | 1992-03-03 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factor |
| US5580560A (en) * | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
| US5225537A (en) * | 1989-12-29 | 1993-07-06 | Zymogenetics, Inc. | Methods for producing hybrid phospholipid-binding proteins |
| CA2073859A1 (en) | 1990-01-26 | 1991-07-27 | Falko-Guenter Falkner | Recombinantly produced blood factors and process for the expression of said blood factors, as well as vaccinia virus recombinants used in said process |
| CA2074839C (en) * | 1990-01-29 | 2000-11-14 | Kathleen L. Berkner | Modified factor vii anticoagulant proteins |
| US5583107A (en) | 1990-09-04 | 1996-12-10 | Cor Therapeutics, Inc. | Agents affecting thrombosis and hemostasis |
| US5531916A (en) * | 1990-10-03 | 1996-07-02 | E. I. Du Pont De Nemours And Company | Hydrofluorocarbon cleaning compositions |
| EP0785273A1 (en) * | 1990-11-26 | 1997-07-23 | Genetics Institute, Inc. | Paired basic amino acid converting enzyme and DNA sequence encoding it |
| JP3459416B2 (ja) | 1991-02-28 | 2003-10-20 | ザイモジェネティクス，インコーポレイティド | 修飾されたファクター▲ｖｉｉ▼ |
| US5788965A (en) * | 1991-02-28 | 1998-08-04 | Novo Nordisk A/S | Modified factor VII |
| US5817788A (en) * | 1991-02-28 | 1998-10-06 | Zymogenetics, Inc. | Modified factor VII |
| US5861374A (en) * | 1991-02-28 | 1999-01-19 | Novo Nordisk A/S | Modified Factor VII |
| US5833982A (en) * | 1991-02-28 | 1998-11-10 | Zymogenetics, Inc. | Modified factor VII |
| US5504064A (en) * | 1991-04-10 | 1996-04-02 | Oklahoma Medical Research Foundation | Treatment of bleeding with modified tissue factor in combination with an activator of FVII |
| JPH0720127A (ja) * | 1993-05-07 | 1995-01-24 | Eisai Co Ltd | 各種ｐｉｖｋａの測定方法および測定試薬 |
| PT699075E (pt) | 1993-05-21 | 2002-05-31 | Novo Nordisk As | Factor vii modificado para inibicao de restenose vascular e de deposicao de plaquetas |
| DE19531637A1 (de) * | 1995-08-28 | 1997-03-06 | Immuno Ag | Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung |
| US5837843A (en) * | 1996-11-08 | 1998-11-17 | Oklahoma Medical Research Foundation | Modified protein C |
| CA2271232C (en) * | 1996-11-08 | 2005-02-22 | Oklahoma Medical Research Foundation | Modified protein c and methods of use thereof |
| AU5773798A (en) | 1997-01-29 | 1998-08-18 | Polymasc Pharmaceuticals Plc | Pegylation process |
| EP1017794A1 (en) | 1997-02-06 | 2000-07-12 | Novo Nordisk A/S | Polypeptide-polymer conjugates having added and/or removed attachment groups |
| AT407255B (de) * | 1997-06-20 | 2001-02-26 | Immuno Ag | Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons |
| US6475725B1 (en) * | 1997-06-20 | 2002-11-05 | Baxter Aktiengesellschaft | Recombinant cell clones having increased stability and methods of making and using the same |
| IL133974A0 (en) | 1997-07-14 | 2001-04-30 | Bolder Biotechnology Inc | Derivatives of growth hormone and related proteins |
| EP1005361B1 (en) | 1997-07-18 | 2010-01-06 | Novo Nordisk Health Care AG | USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ENDOTHELIAL DYSFUNKTION AND FOR THE INHIBITION OF ANGIOGENESIS RESPECTIVELY |
| US7247708B2 (en) * | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6747003B1 (en) * | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6017882A (en) * | 1997-10-23 | 2000-01-25 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6693075B1 (en) * | 1997-10-23 | 2004-02-17 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| AT408613B (de) | 1998-06-17 | 2002-01-25 | Immuno Ag | Pharmazeutisches faktor vii-präparat |
| WO2000026354A1 (en) | 1998-10-30 | 2000-05-11 | Novozymes A/S | Glycosylated proteins having reduced allergenicity |
| DE69916306T2 (de) | 1998-10-30 | 2005-05-04 | Novozymes A/S | Niedrigallergene proteinvarianten |
| JP4463988B2 (ja) | 1998-11-06 | 2010-05-19 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Ｖｉｉ因子の生産方法 |
| AU3629800A (en) | 1999-03-16 | 2000-10-04 | Children's Hospital Of Philadelphia, The | Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors |
| PL204285B1 (pl) * | 2000-02-11 | 2009-12-31 | Bayer Healthcare Llc | Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego |
| US7220837B1 (en) * | 2000-04-28 | 2007-05-22 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| EP1282693B1 (en) | 2000-05-03 | 2010-10-20 | Novo Nordisk Health Care AG | Human coagulation factor vii variants |
| US20030211094A1 (en) * | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
| US7160540B2 (en) * | 2000-06-30 | 2007-01-09 | Regents Of The University Of Minnesota | Methods for detecting activity of clottings factors |
| US6423826B1 (en) | 2000-06-30 | 2002-07-23 | Regents Of The University Of Minnesota | High molecular weight derivatives of vitamin K-dependent polypeptides |
| CZ2003611A3 (cs) * | 2000-09-13 | 2003-08-13 | Novo Nordisk A/S | Varianty lidského koagulačního faktoru VII |
| IL154520A0 (en) | 2000-09-13 | 2003-09-17 | Novo Nordisk As | Human coagulation factor vii variants |
| AU9165201A (en) * | 2000-10-02 | 2002-04-15 | Novo Nordisk As | Factor vii glycoforms |
| WO2002038162A1 (en) | 2000-11-09 | 2002-05-16 | The Scripps Research Institute | MODIFIED FACTOR VIIa |
| CZ20032454A3 (en) | 2001-03-22 | 2004-03-17 | Novo Nordisk Health Care Ag | Coagulation factor vii derivative |
| ES2376694T3 (es) | 2001-09-27 | 2012-03-16 | Novo Nordisk Health Care Ag | Polipã‰ptidos del factor vii de coagulaciã“n humano. |
| AU2002336919A1 (en) | 2001-11-02 | 2003-05-12 | Novo Nordisk Health Care Ag | Human coagulation factor vii polypeptides |
| ES2325653T3 (es) | 2001-12-21 | 2009-09-11 | Novo Nordisk Health Care Ag | Composicion liquida de polipeptidos del factor vii. |
| BR0309576A (pt) | 2002-04-30 | 2005-02-09 | Maxygen Holdings Ltd | Variante de polipeptìdeo do fator vii (fvii) ou fator viia (fviia), sequência de nucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, uso de uma variante, e, método para tratar um mamìfero que tenha uma doença ou um distúrbio em que a formação de coágulo é desejável |
| CA2502162C (en) | 2002-09-30 | 2014-04-15 | Bayer Healthcare Llc | Fvii or fviia variants having increased clotting activity |
| AU2004221761B2 (en) * | 2003-03-20 | 2010-01-07 | Bayer Healthcare Llc | FVII or FVIIa variants |
| US20060116324A1 (en) * | 2003-06-13 | 2006-06-01 | Novo Nordisk Healthcare A/G | Novel formulations |
| DE602004025576D1 (de) * | 2003-06-19 | 2010-04-01 | Bayer Healthcare Llc | Varianten der faktor-vii- oder -viia-gla-domäne |
-
2004
- 2004-06-18 DE DE602004025576T patent/DE602004025576D1/de not_active Expired - Lifetime
- 2004-06-18 MX MXPA05013769A patent/MXPA05013769A/es active IP Right Grant
- 2004-06-18 CA CA2529828A patent/CA2529828C/en not_active Expired - Fee Related
- 2004-06-18 JP JP2006515723A patent/JP4915918B2/ja not_active Expired - Fee Related
- 2004-06-18 PL PL04738925T patent/PL1644504T3/pl unknown
- 2004-06-18 BR BRPI0411650-0A patent/BRPI0411650A/pt not_active IP Right Cessation
- 2004-06-18 AT AT04738925T patent/ATE458057T1/de active
- 2004-06-18 PT PT04738925T patent/PT1644504E/pt unknown
- 2004-06-18 NZ NZ544728A patent/NZ544728A/en unknown
- 2004-06-18 RU RU2006101391/13A patent/RU2373282C2/ru not_active IP Right Cessation
- 2004-06-18 HR HR20100264T patent/HRP20100264T1/hr unknown
- 2004-06-18 WO PCT/DK2004/000428 patent/WO2004111242A1/en not_active Ceased
- 2004-06-18 ES ES04738925T patent/ES2338425T3/es not_active Expired - Lifetime
- 2004-06-18 CN CN2004800237774A patent/CN1839203B/zh not_active Expired - Fee Related
- 2004-06-18 EP EP04738925A patent/EP1644504B8/en not_active Expired - Lifetime
- 2004-06-18 SI SI200431396T patent/SI1644504T1/sl unknown
- 2004-06-18 AU AU2004247799A patent/AU2004247799B2/en not_active Ceased
- 2004-06-18 KR KR1020057024386A patent/KR101191779B1/ko not_active Expired - Fee Related
- 2004-06-18 DK DK04738925.9T patent/DK1644504T3/da active
- 2004-06-18 NZ NZ573412A patent/NZ573412A/en not_active IP Right Cessation
- 2004-12-22 US US11/021,239 patent/US20050164932A1/en not_active Abandoned
-
2005
- 2005-12-05 IL IL172364A patent/IL172364A/en not_active IP Right Cessation
-
2006
- 2006-01-19 ZA ZA2006/00539A patent/ZA200600539B/en unknown
- 2006-04-21 US US11/379,664 patent/US20060252128A1/en not_active Abandoned
- 2006-06-14 US US11/424,035 patent/US8987202B2/en not_active Expired - Fee Related
- 2006-06-14 US US11/424,030 patent/US7807638B2/en not_active Expired - Fee Related
- 2006-12-21 US US11/643,535 patent/US20070117756A1/en not_active Abandoned
-
2010
- 2010-03-02 AU AU2010200793A patent/AU2010200793B2/en not_active Ceased
- 2010-04-23 CY CY20101100374T patent/CY1109984T1/el unknown
-
2011
- 2011-12-20 JP JP2011277848A patent/JP5580283B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012105650A5 (enExample) | ||
| JP2006527982A5 (enExample) | ||
| JP2012095641A5 (enExample) | ||
| RU2004134726A (ru) | Варианты полипептида фактора vii или viia | |
| JP2006521098A5 (enExample) | ||
| JP2005270110A5 (enExample) | ||
| HRP20100264T1 (hr) | Varijante gla domene faktora vii ili viia | |
| RU2002124129A (ru) | Молекулы, подобные фактору vii или viia | |
| CA2519873A1 (en) | Fvii or fviia variants | |
| CN101557830B (zh) | 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物 | |
| JP2006517089A5 (enExample) | ||
| JP2014513952A5 (enExample) | ||
| TW200942258A (en) | Factor VII polypeptides that are modified and uses thereof | |
| AU2013219935B2 (en) | Long-acting coagulation factors and methods of producing same | |
| RU2010137743A (ru) | Конъюгированные молекулы фактора viii | |
| WO2006108718B1 (en) | Micro rna | |
| JP2015521589A (ja) | プロコアグラント化合物 | |
| JP2013163674A5 (enExample) | ||
| JP2010530238A5 (enExample) | ||
| CA2989990A1 (en) | Long-acting coagulation factors and methods of producing same | |
| JP2010513327A5 (enExample) | ||
| JP2016540739A (ja) | 神経保護ペプチド | |
| RU2010144014A (ru) | Применение пегилированных вариантов ифр-i для лечения нейромышечных расстройств | |
| RU2017124487A (ru) | НОВЫЙ ПЕПТИД-ИНГИБИТОР PI3Kγ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ОРГАНОВ ДЫХАНИЯ | |
| JP2012521366A5 (enExample) |